Marshwinds Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
$4.52M Sell
39,030
-649
-2% -$72.5K 2.42% 6
2018
Q3
$4.26M Sell
39,679
-298
-0.7% -$29.8K 1.95% 12
2018
Q2
$3.41M Buy
39,977
+1
+0% +$82 1.61% 22
2018
Q1
$3.09M Buy
39,976
+2
+0% +$161 1.47% 25
2017
Q4
$3.38M Sell
39,974
-749
-2% -$63.7K 1.56% 22
2017
Q3
$3.48M Sell
40,723
-498
-1% -$40.8K 1.62% 23
2017
Q2
$3.39M Sell
41,221
-599
-1% -$48.9K 1.6% 22
2017
Q1
$3.52M Sell
41,820
-323
-0.8% -$25.9K 1.64% 22
2016
Q4
$3.1M Buy
42,143
+2
+0% +$149 1.48% 25
2016
Q3
$3.38M Buy
42,141
+1
+0% +$80 1.65% 19
2016
Q2
$3.32M Sell
42,140
-439
-1% -$33K 1.62% 20
2016
Q1
$3.07M Sell
42,579
-423
-1% -$32K 1.57% 20
2015
Q4
$3.62M Buy
43,002
+1
+0% +$83 1.89% 13
2015
Q3
$3.6M Sell
43,001
-1,173
-3% -$99K 1.93% 10
2015
Q2
$3.69M Sell
44,174
-799
-2% -$60.9K 1.86% 14
2015
Q1
$3.27M Sell
44,973
-748
-2% -$53.3K 1.55% 19
2014
Q4
$3.15M Sell
45,721
-374
-0.8% -$25.2K 1.49% 19
2014
Q3
$2.99M Buy
46,095
+102
+0.2% +$6.46K 1.48% 20
2014
Q2
$2.86M Buy
45,993
+174
+0.4% +$10.4K 1.38% 23
2014
Q1
$2.7M Buy
45,819
+696
+2% +$38.8K 1.36% 23
2013
Q4
$2.3M Buy
45,123
+627
+1% +$31.4K 1.22% 27
2013
Q3
$2.24M Buy
44,496
+527
+1% +$27.6K 1.29% 26
2013
Q2
$2.16M Buy
+43,969
New +$2.39M 1.28% 26

Other funds holding LLY

Marshwinds Advisory's LLY Position: Q4 2018 in Review

Marshwinds Advisory reduced its Eli Lilly (LLY) stake by 1.6% in Q4 2018, selling an estimated $72.5K and leaving 39,030 shares worth $4.52M. The position accounts for 2.42% of the portfolio, ranked #6.

Marshwinds Advisory first reported a position in LLY in Q2 2013 and has held it in 23 quarters since. 1,561 funds tracked by Wall St. Rank hold LLY as of Q4 2018.

  • Marshwinds Advisory held 39,030 shares of Eli Lilly worth $4.52M as of Q4 2018.
  • Marshwinds Advisory sold 649 Eli Lilly shares in Q4 2018, an estimated $72.5K.
  • Eli Lilly made up 2.42% of Marshwinds Advisory's portfolio in Q4 2018, its #6 holding.
  • Marshwinds Advisory first reported a position in Eli Lilly in Q2 2013 and has held it in 23 quarters since.
  • 1,561 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2018.

Based on Marshwinds Advisory's 13F filing for Q4 2018, filed 7 Jan 2019.